

![]() |
Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trial |
|
Authors | ||
Published in | Annals of the rheumatic diseases. 2012, vol. 71, no. 4, p. 560-2 | |
Abstract | Two subcutaneous injections of adalimumab in severe acute sciatica significantly reduced the number of back operations in a short-term randomised controlled clinical trial. | |
Keywords | Acute Disease — Adult — Anti-Inflammatory Agents/administration & dosage/therapeutic use — Antibodies, Monoclonal, Humanized/administration & dosage/therapeutic use — Back Pain/etiology — Diskectomy — Double-Blind Method — Female — Follow-Up Studies — Humans — Injections, Subcutaneous — Kaplan-Meier Estimate — Magnetic Resonance Imaging — Male — Middle Aged — Sciatica/complications/drug therapy/surgery — Treatment Outcome — Tumor Necrosis Factor-alpha/antagonists & inhibitors | |
Identifiers | PMID: 21998121 | |
Full text | ||
Structures | ||
Research group | Mécanisme de l'inflammation articulaire (44) | |
Citation (ISO format) | GENEVAY, Stéphane et al. Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trial. In: Annals of the rheumatic diseases, 2012, vol. 71, n° 4, p. 560-2. doi: 10.1136/annrheumdis-2011-200373 https://archive-ouverte.unige.ch/unige:32498 |